#JITC Research: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells https://t.co/apGGBLGGPj https://t.co/XfnWTAKImT
#JITC Research: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells https://t.co/apGGBLGGPj https://t.co/nH1MSYqm5o
In vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML #gdTcells @JKuball https://t.co/PW4TNG9IwE
Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. https://t.co/ArGTB4r14U https://t.co/1IZXC40jty
New #JITC Research: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells https://t.co/apGGBLGGPj https://t.co/g41B4msWli
Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells #CAR T cells #gammadelta T cells https://t.co/7SlzTsDfIs